Search results
Gilead’s Twice-Yearly Shot Prevents HIV. Where the Stock Is Headed.
Barrons.com· 4 days agoGilead said Descovy holds 40% of the U.S. market for HIV prophylactic medicines, known as HIV PrEP....
UnitedHealth unit to pay New York $1M over birth control step therapy move
BenefitsPRO· 3 days agoNew York state officials gave health insurers a lesson Thursday on the breadth of the state's...
Drug Names: The machinations behind the monikers
Quartz· 6 days agoIn fact, naming a prescription drug can take a manufacturer up to four years, as a set of three monikers per medicine must run the gauntlet of several regulatory agencies.
Appeals court finds 'Obamacare' pillar unconstitutional in suit over HIV-prevention drug
NBC NEWS· 3 days agoThe lawsuit centered on the objections of a coalition of small businesses in Texas to the...
ANI Pharmaceuticals bolsters rare disease business with $381M acquisition
Star Tribune (Minneapolis) via Yahoo Finance· 4 hours agoANI Pharmaceuticalsis doubling down on its rare diseases business — deemed its biggest driver of...
Gateway - Quartz
Quartz· 6 days agoThe US is in a drug shortage emergency. According to the latest Food and Drug Administration (FDA) update, 1450 pharmaceutical products—from antivirals ...
Eli Lilly is cracking down on knock-off versions of its popular weight loss drug Zepbound
Quartz· 4 days agoEli Lilly said Thursday that it is taking legal action against six entities for selling unapproved...
Trial: Fenofibrate Slows Diabetic Retinopathy Progression
Medscape· 2 days agoThe old, generic cholesterol drug fenofibrate has shown potential for slowing the progression of...
Pyros wins FDA approval for ready-to-use infantile spasm treatment
Pharmaceutical Technology via Yahoo Finance· 6 days agoLundbeck gained US commercialisation rights to the drug from Sanofi. Sabril is available as 500mg...
Subtle victory for Sanders in Novo spat
Politico· 6 days agoThe FDA approved Merck’s Keytruda with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adults with primary advanced or recurrent endometrial cancer. The FDA issued final ...
